eTRANSAFE is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. eTRANSAFE has received support from IMI2 Joint Undertaking under Grant Agreement No. 777365. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Start date: 1st September 2017 - End date: 31st August 2022
IMI funding: EUR 20,000,000.0051%
EFPIA in-Kind contribution: EUR 19,490,899.0049%
Total: EUR 39,490,899.00100%